Latest News about BIOVF
Recent news which mentions BIOVF
Merck Virus Treatment Shows 60.4% Effectiveness, Reduces Certain Infections In Infants
October 18, 2024
From Benzinga
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
August 08, 2024
From Benzinga
Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants
October 16, 2023
From Benzinga
Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
June 09, 2023
From Benzinga
Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study
May 25, 2023
From Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
May 11, 2023
From Benzinga
Why Shares of CTI BioPharma Are Soaring Wednesday
May 10, 2023
From Motley Fool
From Benzinga
Selecta, SOBI's Chronic Refractory Gout Program Meets Primary Goal, US Submission Expected Next Year
March 21, 2023
From Benzinga
From Benzinga
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
November 04, 2022
From Benzinga
Sanofi's Hemophilia Candidate Goes Under Priority FDA Review
August 30, 2022
From Benzinga
From Benzinga
SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis
July 11, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.